Im Bereich Forum:
Übersicht Gesamt Börse Hot-Stocks Talk Chat Profil ändern Richtlinien

Suchbegriff:

Antwort einfügen | Zurück zum Börsenforum
Postings im Thread
Wertung Thema Autor Zeit

TEVA -- Zukunft mit Generika



Thema wurde 382628 mal gelesen , umfaßt 1470 Postings und wurde mit 9 Punkten bewertet.

Thread-Navigator:



Neuester Beitrag

1 2 3 4 ... 56 57 58 59
9 1.  TEVA -- Zukunft mit Generika 29411 Postings, 4275 Tage 14051948Kibbu. 27.08.08 18:01
 

Über das israelische Pharmaunternehmen TEVA muß man nicht viel sagen,der auf Generika spezialisierte Pharmakonzern gehört zu den bekanntesten Unternehmen Israels.

 

Neue Studienergebnisse zu Parkinson Medikament

ADAGIO Trial Results Show Teva´s AZILECT(R) 1 mg Tablets Slow Progression of Parkinson´s Disease

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA  videos nachrichten) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain as part of a "Late Breaking News" session.

The ADAGIO study showed that Parkinson´s disease (PD) patients who took AZILECT(R) (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated the drug 9 months later.

The 1mg dose met all three primary endpoints, as well as the secondary endpoint, with statistical significance.  The primary analysis included three hierarchical endpoints based on Total-UPDRS (Unified Parkinson´s Disease Rating Scale) scores:

A) superiority of slopes in weeks 12-36 (-0.05; p=0.013, 95%CI -0.08,-0.01),

B) change from baseline to week 72 (-1.7 units; p=0.025, 95%CI -3.15,-0.21), and

C) non-inferiority of slopes (0.15 margin) in weeks 48-72 (0.0; 90%CI -0.04,0.04).

The safety profile of AZILECT(R) seen in the ADAGIO study was similar to previous experience with AZILECT(R).

Main results were presented at the congress by Professor Olivier Rascol, M.D., Ph.D., Department of Clinical Pharmacology, University Hospital, Toulouse, France, one of two principal investigators of the trial.

"The rigorous trial design and the fact that all three primary endpoints were met with statistical significance reinforce the quality of the data, supporting the potential for AZILECT(R) to have an effect on disease progression," said Prof. Rascol.

"The successful outcome of the study provides further rationale for the early use of AZILECT(R) among Parkinson´s disease patients," he added. "Delaying disease progression is the most important unmet need in the management of Parkinson´s disease," stated Prof. C. Warren Olanow, professor and chairman of the Department of Neurology at the Mount Sinai School of Medicine, New York, NY, and ADAGIO co-principal investigator.

"The ADAGIO study, the first of its kind, was prospectively designed to demonstrate if AZILECT(R) can slow down the progression of Parkinson´s disease. Results of the study show that early treatment with once-daily rasagiline 1mg tablets provided significant clinical benefits that were not obtained by those patients where initiation of AZILECT(R) therapy was delayed by nine months."

 The ADAGIO study, one of the largest conducted in PD, included 1,176 patients with very early Parkinson´s disease in 14 countries and 129 medical centers who were randomized to receive rasagiline 1 or 2 mg/day for 72 weeks (early start) or placebo for 36 weeks followed by rasagiline 1 or 2 mg/day for 36 weeks (delayed start).

Description of trial results can be found online (http://www.abstracts2view.com/ana) in the abstract submitted by Prof. Olanow and Prof. Rascol to the 133rd Annual Meeting of the American Neurological Association, Salt Lake City, UT, September 21-24, 2008.

Prof. Olanow will be presenting these results during the Works in Progress poster session on Tuesday, September 23, 2008. The abstract was also chosen to be presented orally by Prof. Olanow on Tuesday from 11:45am-noon.

Teva intends to submit these results to the regulatory authorities in the U.S. and Europe. Based on these results, Teva will work with the regulatory authorities to incorporate the results into the label for AZILECT(R).

For more information on AZILECT(R), please visit www.azilect.com.

About the Study  

ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group study prospectively examining rasagiline´s potential disease-modifying effects in 1,176 patients with early, untreated Parkinson´s disease.

Patients from 129 centers in 14 countries were randomized to early-start treatment (72 weeks rasagiline 1 or 2 mg once daily) or delayed-start treatment (36 weeks placebo followed by 36 weeks rasagiline 1 or 2 mg once daily (active treatment phase)).

The primary analyses of the trial were based on change in total UPDRS (Unified Parkinson´s Disease Rating Scale) and included slope superiority of rasagiline over placebo in the placebo-controlled phase, change from baseline to week 72, and non-inferiority of early-start vs. delayed-start slopes during weeks 48-72 of the active phase. UPDRS is the most commonly used rating scale to assess disease status.

About AZILECT (R)  

AZILECT(R) 1mg tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson´s disease both as initial therapy alone and to be added to levodopa later in the disease. AZILECT(R) 1mg tablets are currently available in 30 countries, including the US, Canada, Israel, Mexico, and most of the EU countries.

About Parkinson´s Disease

Parkinson´s disease is an age-related degenerative disorder of the brain.

Symptoms can include: tremor, stiffness, slowness of movement, and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60.

About Teva  

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world´s leading generic pharmaceutical company.

The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products.

Over 80 percent of Teva´s sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:  This release contains forward-looking statements. Such statements are based on management´s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva´s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements, including statements relating to the results of the ADAGIO phase III trial and the potential efficacy or future market or marketability of AZILECT(R).

Following further analysis, Teva´s interpretation of the results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release as there can be no guarantee that the results from the phase III trial discussed in this press release will be confirmed upon full analysis of the results of the trial and additional information relating to the safety, efficacy or tolerability of AZILECT(R) may be discovered upon further analysis of data from the phase III trial.

Even if the results described in this release are confirmed upon full analysis of the ADAGIO study, we cannot guarantee that AZILECT(R) will be approved for marketing in a timely manner, if at all, by regulatory authorities in the EU or in the U.S. Additional risks relating to Teva and its business are discussed in Teva´s Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


-----------
"Ein Deutscher ist ein Mensch,der keine Lüge aussprechen kann, ohne sie selbst zu glauben"(Theodor W. Adorno)
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
7x Interessant ,
1x Gut analysiert ,
1x Witzig
Seite 1 2 3 4 5 6 ... 54 55 56 57 58 59    << Zurück Weiter >>
1444 Postings ausgeblendet.
  1446.  soll sie ruhig auf 14$ fallen... 224 Postings, 155 Tage amorphis 12.10.18 15:27
 
...kaufe ich dann noch lieber auf dem niveau. Ich habe Zeit.

https://www.ajovy.com/...&utm_campaign=Branded&utm_term=ajovy approval&utm_content=Ajovy_Exact&gclid=CImsuYb0_t0CFYnrDQodQtIDOg&gclsrc=ds&dclid=CL2r0Ib0_t0CFYl_wQodGX4FvA

now available ;-)  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1447.  Bleibe drin, denke der Kurs konsolidiert 1632 Postings, 373 Tage Körnig 12.10.18 23:32
 
nicht mehr lange. Dann wird es wieder nachhaltig steigen.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1448.  Ja kurzfristig 235 Postings, 341 Tage Tekoshin 13.10.18 20:08
 
25€     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1449.  dauert. ich mehr 235 Postings, 341 Tage Tekoshin 15.10.18 08:25
 
lang die seitwärtsbewegung endet demnächst!     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1450.  TEVA 443 Postings, 447 Tage shuntifumi 17.10.18 16:54
 
Hier die Meldung zum heutigen Kursrutsch. Sicher ein Dämpfer, der Grund für die Nichtberücksichtigung wäre mal interessant. Für 2018 umsatztechnisch sicher irrelevant. Für die Zukunft aber von Bedeutung. Ich bin gespannt, ob sich Teva noch dazu äußert.

http://www.deraktionaer.de/aktie/...ne-attacke-aus-den-usa-404520.htm  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
1x Gut analysiert
  1451.  Grund für Nichtberücksichtigung... 224 Postings, 155 Tage amorphis 18.10.18 15:56
 
...wahrscheinlich zahlt AMGN gut damit die Konkurrenz es schwer hat ;-)     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1452.  Viel wichtiger... 224 Postings, 155 Tage amorphis 18.10.18 15:59
 
ist doch:

https://www.reuters.com/article/...-drugs-excludes-teva-idUSKCN1MR1IA

Teva, in an emailed statement, said it was “disappointed” with Express Scripts’ decision, but has programs in place to make sure patients can access Ajovy, which is seeing “strong demand” in the few weeks since its launch.

=> strong demand!

Es ist das einzige Mittel welches quartalsweise verabreicht werden kann. Welches würdet ihr denn nehmen wollen ;-)  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1453.  Die Nachricht 224 Postings, 735 Tage Sylar88 20.10.18 14:47
 
von oben ist objektiv schlecht. Teva Produkt wird nicht genommen. = schlechte Nachricht.

Was soll Teva im Statement sonst sagen ? Die Konkurrenz hat ihre Produkte zu einem besseren Preis angeboten und Teva nicht. Starke Nachfrage muss Teva schreiben. Man muss das so lesen: Trotz der starken Nachfrage und obwohl 2-3 andere Produkte genommen worden sind, ist das Produkt von Teva nicht genommen worden.  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1454.  Du meinst also... 224 Postings, 155 Tage amorphis 20.10.18 17:26
 
...das Teva einfach mal öffentlich von einer starken Nachfrage sprechen kann, obwohl diese "schwach" ist? Das glaube ich kaum ;-)     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1455.  ... 224 Postings, 735 Tage Sylar88 20.10.18 23:38
 
1) Wenn so eine starke Nachfrage vorhanden ist und das Produkt von Teva nicht genommen wird ist es schlecht.
2) Ich kenne den Grund nicht warum. Laut dem Artikel bieten alle Anbieter die Produkte zum gleichen Preis an. Anscheinend gewähren die anderen entweder einen höheren Preisnachlass als Teva, was den Versicherungen mehr entgegen kommt oder die anderen Produkte sind eventuell besser. Warum die anderen Produkte jetzt bevorzugt werden kenne ich nicht.
Darum Ja ich halte das für keine gute Nachricht für Teva.

Bin derzeit etwas skeptisch was Teva langfristig betrifft. Konkurrenz schläft leider nicht. Da ich erst am Anfang bin mich intensiv in das Unternehmen einzulesen, sollte man meiner Meinung/Postings nicht so viel Beachtung schenken.  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1456.  Das war leider nichts! Muss das Geld halt mit was 1632 Postings, 373 Tage Körnig 22.10.18 13:48
 
anderem verdient werden:) Mit Nachkaufen warte ich erstmal.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1457.  Körnig...Geduld ;-) 224 Postings, 155 Tage amorphis 22.10.18 14:41
 
Teva wird sich schon noch positiv entwickeln. Ich persönlich habe hier 3-5 Jahre eingeplant - mindestens.

News von heute...

https://finance.yahoo.com/news/...ical-signs-agreement-114708748.html  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
1x Gut analysiert
  1458.  Und zum Thema "strong demand" 224 Postings, 155 Tage amorphis 22.10.18 14:45
 
=> Teva wird das nicht einfach so offiziell kundgeben dürfen. Warum sollten sie das tun? Um eine Klagewelle zu riskieren wegen Falschaussagen? Um das Vertrauen in die Restrukturierungsmaßnahmen der letzten Monate zu vernichten? In weniger als 2 Wochen gibt es Zahlen zum dritten Quartal. Bin insbesondere auf den Ausblick gespannt.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
1x Interessant
  1459.  wie in #1440 bereits von mir erwartet... 224 Postings, 155 Tage amorphis 01.11.18 13:02
 
...sehen wir hier die nächste Erhöhung des Ausblicks.

Teva Pharm raises 2018 profit outlook after Q3 tops estimates
   Reuters§Reuters•November 1, 2018
(Adds details, CEO quote)

By Tova Cohen

TEL AVIV, Nov 1 (Reuters) - Teva Pharmaceutical Industries raised its earnings outlook for 2018 on Thursday and said it was seeing "very good signs of a successful launch" for its long-awaited migraine treatment Ajovy .

Israel-based Teva, the world's largest generic drugmaker, has been counting on Ajovy to revive its fortunes after it was forced to restructure to tackle a debt crisis.

The release of the migraine drug had been delayed due to U.S. regulatory concerns about the manufacturing process, but Ajovy finally won approval from the U.S. Food and Drug Administration in September.

Ajovy suffered a setback in October when Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, said it will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude Teva's treatment.

Israel-based Teva said it had earned 68 cents per share excluding one-time items in the July-September period, down from $1.00 a year earlier.

Analysts had forecast Teva would earn 54 cents a share ex-items on revenue of $4.53 billion, according to I/B/E/S data from Refinitiv.

Teva confirmed its revenue fell 19 percent to $4.53 billion due to generic competition to its multiple sclerosis drug Copaxone, price erosion in its U.S. generics business and a loss of revenue from the divestment of some of its products and the discontinuation of some activities.

North American sales of Copaxone tumbled 43 percent in the quarter to $463 million while generic product sales in North America fell 25 percent.

Teva raised its full-year forecast for adjusted EPS to $2.80-$2.95, from a previous estimate of $2.55-$2.80.

"Our restructuring plan has already resulted in a significant cost reduction of $1.8 billion in the first nine months of the year and we are on track to achieve a reduction of $3.0 billion by the end of 2019, while continuing to pay down our debt," Teva Chief Executive Kare Schultz said. (Reporting by Tova Cohen Editing by Steven Scheer)  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1460.  Bei der aktuellen EPS Prognose ... 224 Postings, 155 Tage amorphis 01.11.18 13:22
 

...reden wir hier von einem KGV von knapp über 7! Eigentlich interessiert mich das KGV nicht sonderlich, ich achte da vielmehr auf das Gewinnwachstum. Aber man kann jetzt nicht grad sagen, Teva sei teuer bewertet ;-)


Hier noch die Meldung ausführlicher:

https://finance.yahoo.com/news/...s-third-quarter-2018-110000876.html

 
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
1x Informativ
  1461.  3rd. quarter .. 231 Postings, 649 Tage KalleZ 01.11.18 14:39
 
Buffet hat mal wieder die Nase gehabt.
Die packen es mit Kare von Lundbeck.
In drei Jahren steht die Aktie wieder bei den Kursen vor dem Absturz.  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1462.  Ratiopharm-Mutter 686 Postings, 231 Tage neymar 01.11.18 16:08
 
Ratiopharm-Mutter etwas zuversichtlicher

https://www.teleboerse.de/aktien/...rsichtlicher-article20700472.html  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1463.  chartechnisch... 224 Postings, 155 Tage amorphis 01.11.18 19:20
 
...heute mit einem Schlag die 38 und 200 Tagelinie genommen. Knabbern grad an der 100 Tagelinie ;-)     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Bisherige Bewertungen:
1x Informativ
  1464.  KalleZ 1632 Postings, 373 Tage Körnig 02.11.18 09:20
 
Das wäre schön, aber für mich unrealistisch zum jetzigen Zeitpunkt. Kurse von 30 Euro vielleicht 40 Euro in drei Jahren sind wohl realistischer. Ich bin erstmal froh, wenn ich aus dem Minus raus komme.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1465.  Körnig 231 Postings, 649 Tage KalleZ 02.11.18 09:37
 
30 -40 Euro wären auch nicht schlecht. Geduld . Wird nicht gleichmässig hochgehen.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1466.  @Körnig 224 Postings, 155 Tage amorphis 02.11.18 09:39
 
Ich halte die alten Hochs ebenfalls für möglich. Ob in 2 oder 5 Jahren spielt dabei für mich keine Rolle.


Teva Passes Its Check-Up - WSJ

www.wsj.com

Teva Passes Its Check-Up

Drugmaker’s third-quarter results are strong enough to let investors imagine better days

Nov. 1, 2018 12:04 p.m. ET

The turnaround at Teva Pharmaceutical Industries TEVAremains on schedule.
The generic drug giant reported third-quarter sales of $4.5 billion and adjusted earnings of 68 cents a share. While both figures were down significantly from a year earlier, the earnings figure topped expectations thanks to deeper cost cuts than analysts had anticipated. Teva also increased its full-year guidance for profit and free cash flow.

That may not sound like a great quarter, and Teva’s restructuring program won’t be complete until the end of 2019, yet the stock rose sharply on Thursday.
Investors appear satisfied that new Chief Executive Kare Schultz is making enough progress in battling several familiar obstacles for Teva: too much debt, new competition for a key branded multiple-sclerosis drug and falling generic drug prices in the U.S.
Teva continues to chip away at its net borrowings, which peaked in 2016 at around $35 billion. That balance is now slightly below $30 billion. Sales of multiple-sclerosis drug Copaxone fell after new competitors came online, but new product launches like the migraine drug Ajovy are helping pick up the slack. And, while the pricing environment for generic drugs in the U.S. hasn’t shown much improvement, Mr. Schultz said in an interview that “we are past the period when prices were falling like a stone.”
The stock is still risky to own: Mr. Schultz’s cost cuts mean that earnings before interest, taxes, depreciation and amortization are likely to fall for the third year in a row in 2019. Teva believes that will be the last year of declining profitability, but the timing could slip if, say, U.S. generic prices were to begin falling sharply again.
But the deleveraging should continue, and more positive surprises are possible if all goes well. New experimental drugs, such as a non-opioid pain treatment in late stage trials, could bolster the company’s growth outlook. As debt gets paid down, the chances of a sharper stock rally go up. Shares have doubled from last fall’s multiyear low but are still down nearly 70% since their all-time high in 2015.
The company’s debt-adjusted market value is now about 10 times Ebitda, which isn’t particularly cheap. But the stock trades at a very modest 8 times forward earnings.
Teva isn’t cured yet, but is healthy enough for investors to take a chance.  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1467.  4 Reasons To Buy Teva 224 Postings, 155 Tage amorphis 02.11.18 16:04
 
https://seekingalpha.com/article/4217387-4-reasons-buy-teva     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1468.  Teva... 224 Postings, 155 Tage amorphis 12.11.18 19:45
 
...hält sich erstaunlich gut gegen den Trend. Bis zum 15.11. muss Berkshire seine neuen Käufe/Verkäufe deklarieren. Warten wir mal ab. Ich gehe davon aus das weitere Anteile hinzugekauft wurden. Die jüngste Schwäche hat sich ja geradezu angeboten ;-)     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1469.  Teva 443 Postings, 447 Tage shuntifumi 12.11.18 21:41
 
Gut möglich. Ich habe auch mit mir gehadert, ob ich doch wieder aufstocke. Habe es dann aber doch bei meinen knapp 30 % Depotanteil belassen. Das böse Klumpenrisiko (Trump + Israel), ;)

Die Meldung müsste übrigens schon am 14.11., denke wie immer so kurz nach 22 Uhr MEZ, kommen. Ist ja eine 45 Tage Frist...  
  AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
  1470.  oh stimmt ;-) 224 Postings, 155 Tage amorphis 12.11.18 23:18
 
Hatte ich falsch im Kopf. Ist ja noch besser...morgen wissen wir mehr.     AG-Filter: Teva Pharmaceutica.
Übersicht Kurse Chart
News Forum

Performance seit Posting
Seite 1 2 3 4 5 6 ... 54 55 56 57 58 59    << Zurück Weiter >>

Zurück zum Börsenforum - Antwort einfügen - Zum ersten Beitrag springen
Tue Nov 13 21:49:49 2018
Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?